TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has issued an update.
Neuren Pharmaceuticals Limited announced the cessation of 349,920 ordinary fully paid securities due to an on-market buy-back, effective June 17, 2025. This move is part of the company’s capital management strategy, potentially impacting its share structure and market perception, with implications for investors and stakeholders regarding the company’s financial health and strategic direction.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$27.90 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurological disorders. The company is known for its research and development efforts in creating treatments for conditions such as Rett syndrome and Fragile X syndrome, aiming to address unmet medical needs in these areas.
Average Trading Volume: 723,801
Technical Sentiment Signal: Sell
Current Market Cap: A$1.55B
See more data about NEU stock on TipRanks’ Stock Analysis page.